Start here if you're new
what it is
Novartis makes branded prescription drugs, then sells them worldwide across cancer, immunology, brain, and heart-related diseases.
how it gets paid
Last year Nvs made $54.9B in revenue. Oncology was the main engine at ~$22.1B, or 35% of sales.
what just happened
The cleanest hard number is $3.88 in latest-quarter EPS, up 88% vs. prior year, even as a separate consensus feed showed a miss versus estimates.
At a glance
A++ balance sheet — fortress balance sheet — as safe as it gets
60/100 earnings predictability — reasonably predictable
22.0% return on capital — every dollar works hard here
$63B fy2028 rev est
42.5% operating margin
xvary composite: 97/100 — above average
What they do
Novartis makes branded prescription drugs, then sells them worldwide across cancer, immunology, brain, and heart-related diseases.
Patents (legal exclusivity → temporary monopoly pricing → fat profits) help Novartis turn 42.5% of sales into operating profit and 24.6% into net income. You are paying for a drug portfolio that still earns 30% on equity after spinning off Alcon in 2019 and Sandoz in 2023.
How they make money
$54.9B
annual revenue
Oncology
~$22.1B
Immunology
~$15.8B
Cardiovascular-Renal-Metabolic
~$12.6B
Neuroscience
~$12.6B
The products that matter
heart failure medicine
Entresto
blockbuster brand · part of a $54.9B portfolio
it's one of the medicines behind a stock up 46% in 12 months. if Entresto slows, the path from $54.9B today to the $63B 2028 revenue estimate gets harder.
runway check
breast cancer therapy
Kisqali
oncology driver · supports a 42.5% operating margin
oncology is how large pharma defends premium profitability. in a business earning 42.5% operating margin, growth drugs like Kisqali matter more than their label suggests.
margin support
immunology medicine
Cosentyx
franchise anchor · tied to the current blockbuster cycle
the stock trades at 18.9x earnings because investors think the current roster can keep delivering. Cosentyx is part of that bet whether the market says it out loud or not.
cycle exposure
Key numbers
42.5%
operating margin
Operating margin → profit after running the business → so what: Novartis keeps $42.50 from every $100 of sales before interest and taxes.
$22.6B
debt load
Long-term debt equals just 8% of capital. Plain English: the balance sheet is carrying weight, not dragging the company under it.
100/100
price stability
Price stability → how steady the stock has been → so what: this has traded more like a bond with patents than a biotech lottery ticket.
22.0%
return on capital
Return on capital → profit earned on the money invested in the business → so what: Novartis turns every $1 invested into $0.22 of operating return.
Financial health
A++
strength
- balance sheet grade A++ — the absolute highest — fortress balance sheet
- risk rank 1 — safer than 95% of stocks
- price stability 100 / 100
- long-term debt $22.6B (8% of capital)
- net profit margin 24.6% — keeps 25 cents of every dollar in revenue
- return on equity 30% — $0.30 profit for every $1 investors have put in
A++ with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.
Total return vs. market
You invested $10,000 in NVS 3 years ago → it's now worth $17,190.
The index would have given you $13,920.
source: institutional data · total return
What just happened
missed estimates
The cleanest hard number is $3.88 in latest-quarter EPS, up 88% vs. prior year, even as a separate consensus feed showed a miss versus estimates.
The data is messy. SEC-verified quarterly EPS was $3.88, up 88% vs. prior year, while the consensus snapshot showed $1.25 versus a $1.76 estimate. When sources disagree, the safe takeaway is simple: profits moved sharply, but the market's comparison point did not line up cleanly.
$3.88
eps
n/a
n/a
n/a
n/a
the number that mattered
$3.88 matters because it is the only SEC-verified quarterly earnings figure provided, and it was up 88% from a year earlier.
-
novartis has performed well in 2025.through the first nine months, earnings were up markedly from a year ago, fueled by momentum across several of the swiss drugmaker’s core franchises. recent showings have been highlighted by robust demand for top oncology assets kisqali and pluvicto, as well as multiple sclerosis treatment kesimpta. heart failure medication entresto has also remained a steady contributor, despite an uptick in generic competition. subscribers may recall that novartis put up a stiff defense to block this from happening, but after lengthy litigation, was ultimately unsuccessful and generic versions of entresto were launched in the u.s. in mid-2025.
-
we believe the company is well positioned to keep the ball rolling in 2026.
-
our presentation calls for continued top- and bottom-line improvement next year, albeit at a slower pace than what we saw in 2025.the deceleration largely reflects erosion in entresto, which is expected to intensify in the coming quarters due to the aforementioned competitive pressures. novartis will be leaning heavily on further development/expansion of priority brands kisqali, pluvicto, and kesimpta to lighten the blow. leukemia drug scemblix and cholesterol-fighting leqvio are other assets that should gain further traction in 2026.
-
acquisitions could help to supplement organic growth initiatives.
-
novartis inked a $12 billion deal to acquire avidity biosciences in late-october.if approved, the transaction would provide a significant boost to its neuroscience business, as avidity possesses three promising latestage programs that address genetic muscular diseases.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk here is the current Entresto-Kisqali-Cosentyx cycle losing momentum before the next wave is ready. Novartis looks safe on the balance sheet. Drug portfolios rarely stay safe forever.
med
blockbuster concentration risk
the stock's 46% run is tied to confidence in Entresto, Kisqali, and Cosentyx. if those brands slow sooner than expected, the $63B revenue path starts looking aggressive.
a miss against that growth path would pressure both revenue expectations and the 18.9x multiple investors still consider reasonable today.
med
drug-pricing and antitrust pressure
public-source risk items already flag antitrust pressure in Washington. for a company earning a 42.5% operating margin, policy pressure on pricing matters more than it would for a low-margin business.
margin compression sounds abstract until you remember this business generates $54.9B in revenue. a few points of pressure at that scale is real money.
med
the next act may not show up on schedule
pharma math always comes back to replacement. today's lineup can be excellent and still leave a gap if future approvals, label expansions, or launches arrive late.
that matters because the market is not paying for a turnaround story. it's paying for continuity from $54.9B today toward $63B by 2028.
med
esg, legal, and disclosure noise can hit sentiment fast
a Feb 4, 2026 public-source item flagged a new esg and sustainability risk. the disclosure is thin, which means sizing the impact precisely would be fake precision.
the practical read-through is simpler: when a stock is at a 52-week high, investors suddenly care a lot about any reason to de-risk.
the financial risk is low. the portfolio-cycle and regulatory risk is where the real debate lives.
source: institutional data · regulatory filings · risk analysis
Pay attention to
profitability
42.5% operating margin is the number that protects the story
if that starts slipping while revenue growth stays only modest, the market will stop treating Novartis like a premium defensive name.
trend
46% in 12 months leaves less room for ordinary disappointment
great businesses can still be awkward buys after big runs. from here, results have to keep looking clean.
risk
the blockbuster cycle is the quiet part of the thesis
Entresto, Kisqali, and Cosentyx are doing a lot of narrative heavy lifting. if one wobbles, investors will ask harder questions about the next wave.
flow
watch if institutional net buying makes it three quarters in a row
580 buyers versus 538 sellers in 3q2025 is supportive. another positive quarter would tell you the rally still has sponsorship.
Analyst rankings
earnings predictability
60 / 100
middle-of-the-pack predictability for a pharma name. in human-speak, you should expect steadier numbers than biotech, but not a metronome.
risk rank
1
lower is better here. this says balance-sheet risk is minimal compared with most public stocks.
price stability
100 / 100
the stock has been unusually steady. that's rare for a sector where one trial or policy headline can move sentiment fast.
source: institutional data
Institutional activity
institutions have been net buying for 2 consecutive quarters — 580 buyers vs. 538 sellers in 3q2025. total institutional holdings: 0.1B shares. net buying for 2 quarters.
source: institutional data
Price targets
3-5 year target range
$100
$155
$135
current price
$128
target midpoint · 5% from current · 3-5yr high: $170 (+25% · 9% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive